Abstract Neuropilins are involved in angiogenesis and neuronal development. The membrane proximal domain of neuropilin-1, called c or MAM domain based on its sequence conservation, has been implicated in neuropilin oligomerization required for its function. The c/MAM domain of human neuropilin-1 has been recombinantly expressed to allow for investigation of its propensity to engage in molecular interactions with other protein or carbohydrate components on a cell surface. We found that the c/MAM domain was heavily Oglycosylated with up to 24 monosaccharide units in the form of disialylated core 1 and core 2 O-glycans. Attachment sites were identified on the chymotryptic c/MAM peptide ETGA TEKPTVIDSTIQSEFPTY by electron-transfer dissociation mass spectrometry (ETD-MS/MS). For highly glycosylated species consisting of carbohydrate to about 50 %, useful results could only be obtained upon partial desialylation. ETD-MS/MS revealed a hierarchical order of the initial O-GalNAc addition to the four different glycosylation sites. These findings enable future functional studies about the contribution of the described glycosylations in neuropilin-1 oligomerization and the binding to partner proteins as VEGF or galectin-1.
Introduction
Neuropilins (Nrps) are a family of transmembrane proteins involved in a number of signaling pathways. Of these pathways the two best characterized are angiogenesis in combination with the vascular endothelial growth factor (VEGF) receptor (VEGFR) and neuronal development in combination with plexins. Nrp's ability to bind to multiple structurally unrelated ligands has been attributed to its multidomain architecture with a large ectodomain containing four ligand-binding domains (a1a2b1b2) and a membrain proximal c/MAM domain purportedly involved in Nrp oligomerization [1] . Nrp's functionality can also be altered through a posttranslational modification on the highly conserved Nrp1 S612, which can be O-glycosylated with either heparan sulfate or chondroitin sulfate [2, 3] . Using a S612A mutation a number of functional properties have been attributed to this glycan. With the help of I-125 radiolabelled VEGF Shintani [3] and coworkers showed that the glycosylation increases Nrp affinity for VEGF as well as alters receptor internalization and VEGFR expression levels in smooth muscle cells. Frankel et al. [2] investigated S612 glycosylation effects in highly invasive U87MG human glioma cells and suggested that S612 is modified by chondroitin sulfate exclusively and that loss of this modification is associated with increased invasion properties of the cells. Furthermore, they ascribed this behavior to Nrp1-mediated signaling through p130Cas pathway. S612 is not conserved in Nrp2 thus conferring glycosylation-linked and isoform-specific properties to Nrp1, only. Additional N-linked glycosylation sites have been identified on N150, N261 and N522 [4, 5] with two more sites predicted based on sequence analysis (N300 and N842, Uniprot NRP1_HUMAN), although no functionality has yet been attributed to these putative modifications.
Other roles for glycans associated with neuropilin-1, in both angiogenesis and neuronal development, have also been postulated. It has been shown that galectin-1 (Gal1), through its carbohydrate-recognition domain, binds Nrp1, although the specific carbohydrate and Nrp1 glycosylation site is undetermined [6] . Gal1 is a homo-dimeric lectin with a conserved carbohydrate-binding site capable of binding the β-galactoside units of N-and O-linked sugars [7, 8] . The interaction between Nrp1 and Gal1 increased the migration of HUVEC cells in a VEGFR-2-dependent fashion [6] . In addition, it has been shown that binding of Gal1 to Nrp1 increases the phosphorylation levels of VEGFR-2, thus indirectly implicating formation of a complex multiprotein assembly on the cell surface involving Gal1, glycan-modified Nrp1, VEGF and VEGFR-2. Recently, Quinta et al. [9] have shown that Gal1 can play an important role in neuronal regeneration. Gal1, through interactions with Nrp1 prevents semaphorin3A from binding to the Nrp1:plexin complex required to induce neuronal growth cone collapse. Thus, Gal1:Nrp1 interactions have a wide array of cellular effects on different cell types although the molecular basis of this interaction remains undetermined.
The only well-characterized Nrp1 O-glycosylation site, so far, is S612, a site of covalent attachment for chondroitin / heparan sulphate. Very recently, 5 O-GalNAc glycosylation sites were reported for Nrp1 but without specification of the glycan structures [10] . A stretch of clustered O-glycans (4x in a range of 628-646) in close proximity to the known S612 glycosaminoglycan attachment site might affect the (patho)physiological properties of this part of Nrp1 (c/MAM domain). While Nrp1 is known to bind Gal1, the exact site of lectin binding has not yet been defined and thus knowledge about sites of modifications as well as structures of bound carbohydrates constitutes an essential basis for further functional studies. Tandem mass spectrometry with electrontransfer dissociation (ETD-MS/MS) on an ion trap instrument has recently been applied to the large and complex multisite O-glycopeptide of bovine fetuin [11] and was therefore considered as an appropriate method for the analysis of c/MAM.
Here we present a detailed characterization of the O-linked glycosylation of the c/MAM-domain of Nrp1 by mass spectrometry. The sites of glycosylation (ETD-MS/MS) as well as the chemical structures of the attached carbohydrates (PGC-LC-MS/MS) were determined revealing a hierarchical order of GalNAc-addition to the different modification sites.
Material and methods
cDNA cloning, gene expression and protein purification A portion of the human Nrp1 cDNA, corresponding to protein residues 628-813 was amplified using the following primers: 5′-GCGTAGCTGAAACCGGCGCCACAGAAAAGCCC ACGGTC-3′, and 5′-GTGGTGGTGGTGTTTTGCTGGTTT TGCACAATCTTCTTGTG-3′. By using the In-Fusion (Clontech Saint-German-en-Laye, France) ligation method, the PCR products were inserted into the pOPINTTGNeo vector (Oxford Protein Production Facility, UK) to generate pOPINTTGNeo_MAM. The resulting expression construct encoded a fusion protein that in addition to human Nrp1 c/MAM domain contained an N-terminal secretion tag and the non-cleavable C-terminal His6-tag.
Protein expression was carried out in HEK293 F cells (Invitrogen, Carlsbad, CA, USA) grown in suspension. Typically, 1 l flasks seeded with 250 ml HEK293 F cells at a density of 1.0−1.4×10 6 cells mL −1 were transfected with 312 μg pOPINTTGNeo_MAM plasmid using 470 μg PEI (Sigma Aldrich, Vienna, Austria) mixed in 10 mL OptiPRO SFM media (Life technologies, Vienna, Austria) supplemented with 4 mM L-Glutamine (Sigma Aldrich). The cells were grown in FreeStyle expression media (Life technologies) while shaken at 125 rpm in a CO 2 incubator. Three to four days post transfection the medium was collected and cleared by centrifugation at 3000 g for 15 min, and filtration through 0.45 μm sterile filter. The clarified media was passed through a 1 mL HisTrap FF column (GE Healthcare, Fairfield, CT, USA) pre-equilibrated with 20 mM Tris-HCl pH 8.0 containing 150 mM NaCl. The column, mounted on an Äkta Purifier FPLC (GE Healthcare), was washed with equilibration buffer supplemented with 20 mM imidazole, before the recombinant protein product was eluted in 20 mM Tris-HCl pH 8.0 plus 150 mM NaCl and 500 mM imidazole. The protein was immediately concentrated to about 10 mg mL -1 by centrifugation with a 10 kDa cutoff concentrator (Millipore, Vienna, Austria) spun at 4000 x g and subjected to size exclusion chromatography on a Superdex S200 10/300 GL column (GE Healthcare) equilibrated in 20 mM Tris pH 8.0, 150 mM NaCl. Purified protein eluted from the size exclusion column as a single symmetrical peak (Supplementary Figure 1) . No contaminating protein bands were visible in a Coomassie Blue-stained 15 % SDS-PAGE gel of the eluted fractions corresponding to the main protein peak. About 1 mg of protein per each 1 L flask were reproducibly generated. Removal of the secretion tag by HEK293 cells and the identity of the Nterminal residue were verified by mass spectrometry analysis as described below. The protein was stored in 20 mM Tris pH 8.0, 150 mM NaCl at −80°C before further analysis.
Reductive beta-elimination of O-glycans
O-glycans of the recombinant c/MAM domain (50 μg in 10 μl) were released with 1 M sodium borohydride in 100 mM NaOH and purified with Hypercarb SPE cartridges (Hypersep Hypercarb, 25 mg, Thermo Scientific, Vienna). Characterization of these glycans was done via LC-ESI-MS on a porous graphitic carbon (PGC) column (100×0.32 mm, Hypercarb, Thermo Scientific) using a Dionex Ultimate 3000 nano-HPLC coupled to an amaZon ion trap (Bruker, Bremen, Germany) as detailed recently [11] . Briefly, glycans were separated within 30 min by applying 1 to 28 % acetonitrile (solvent A 65 mM ammonium formate, pH 3.0) with a flow rate of 6 μl/min and detected in positive ion mode.
Intact mass measurement
The c/MAM-domain (5 μg) was directly taken for an LC-ESI-MS analysis using a Dionex Ultimate 3000 nano-LC system and a Bruker maXis 4G. The protein was run on a C-5 separation column (Discovery BIO Wide Pore C-5, 50×32 mm, 3 μm, Supelco / Sigma Aldrich) at a flow rate of 7 μl /min. After flushing the column for 5 min with 10 % acetonitrile (solvent B) in 0.1 % formic acid (solvent A), a gradient up to 75 % acetonitrile within 25 min was applied. Protein species were detected with a modified tune_high method of Bruker with the following settings adapted: mass range 350 -3000 m/z, spectra rate 0.8 Hz, transfer time and ion cooler RF in basic stepping mode from 91 to 120 μs and from 450 to 700 Vpp, pre pulse storage 14 μs, low mass 400 m/z and in-source CID 30 Ev. Generated protein mass spectra were summed up in a range of 2 min and deconvoluted in Bruker's Data A n a l y s i s 4 .0 us i n g m a x i m u m e nt r o py ch a rg e deconvolution. 
Fractionation of O-glycopeptides
For initial analysis, the c/MAM-domain (10 μg) was reduced, S-alkylated and digested either with sequencing grade modified trypsin (Promega, Madison, WI, USA) or chymotrypsin (Roche, Vienna, Austria) as described [12] . Subsequent analysis of the generated (glyco)peptides was done via reversedphase LC-ESI-MS/MS with the said Dionex-HPLC and a maXis 4G Q-TOF MS (Bruker) [11] . For thorough O-glycopeptide analysis, 3 mg of S-alkylated c/MAM was digested with chymotrypsin (Roche, Vienna, Austria) overnight 37°C at a substrate to enzyme ration of 1:200. Peptides were fractionated on a BioBasic18 column (250×4 mm, 5 μm pore size, Thermo Scientific) with 1 mL min -1 flow rate with 65 mM ammonium formate of pH 3.0 as solvent A. Glycopeptides were collected in 1 min intervals between 14 and 27 % acetonitrile (solvent B) within 40 min. Fractions were dried in vacuum, taken up in 200 μL water and a 1 μL portion was analyzed via LC-ESI-MS with a very steep gradient to 75 % acetonitrile in 10 min (6 μl min -1 ) on a capillary BioBasic18 column. Glycopeptides were detected on an Ultima Global Q-TOF MS (Waters-Micromass, Manchester, UK).
Fractions of interest were divided and either analyzed as such or after desialylation. To this end, 50 μL aliquots were dried and redissolved in 50 μL neuraminidase buffer (5 mM CaCl 2 in 50 mM sodium acetate buffer, pH 5.5) and digested with 1 μL (50 units) α2-3,6,8 neuraminidase (New England Biolabs, Frankfurt/Main, Germany) on 37°C for 16 h. The glycopeptide species were subsequently purified using C-18 solid phase extraction cartridges (Hypersep C-18, 25 mg, Thermo Scientific). Conditioning was done with 500 μl 80 % acetonitrile (including 0.1 % formic acid) and two flushes with 500 μl 0.1 % formic acid. The samples were applied, washed once with 500 μl 0.1 % formic acid, eluted with 80 % acetonitrile plus 0.1 % formic acid and dried in vacuum.
ETD analysis
ETD-MS/MS experiments of the fractions of interest were performed with online LC separation and detection on a Bruker amaZon ion trap equipped with a nanoBooster CaptiveSpray source. Glycopeptides were flushed onto a C-18 trapping column (C-18 PepMap100, 300 μm×5 mm, Thermo Scientific, 20 μL min -1 flow rate), then applied to a separation column (Acclaim PepMap RSLC 75 μm×250 mm, 2 μm, Thermo Scientific) at a flow rate of 300 nL min -1 and eluted with a gradient from 13 to 40 % acetonitrile in 50 min. The electrospray settings were 1400 V capillary voltage, 500 V end plate offset, 0.2 bar nebulizer pressure, 3 L min -1 nitrogen gas flow and 150°C drying gas temperature. The gas flow was guided through 100 % acetonitrile in the nanoBooster device. The actual ETD reaction was done in Manual MS(n) mode with a 4 Da precursor selection window and ETD reagent times between 40 and 80 ms, depending on the precursor m/z and z values. The ETD data was processed in Data Analysis using the SNAP algorithm for generating average mass spectra of about 1-4 min (about 20-80 single ETD spectra), depending on the peak width. Other ETD settings, procedures and further data evaluation by BioTools 3.2 were done as described [11] .
Results and discussion

Intact mass analysis of c/MAM
In SDS-PAGE the purified c/MAM domain exhibited an apparent mass of about 25 kDa, which considerably exceeds the expected 22 kDa (Supplementary Figure 1) . Glycosylation was assumed as the reason for this discrepancy. To get an impression of the degree of glycosylation the recombinant c/MAM domain was subjected to intact protein mass determination on a high-resolution Q-TOF instrument (Fig. 1) . Intervals of 365 and 291 Da between major peaks indicated the complex pattern to be caused by differently glycosylated protein species. No unglycosylated c/MAM domain could be detected (22.308 kDa average mass, range not shown in Fig. 1 ). The mass differences between experimental peaks and the calculated protein mass suggested the attachment of several mucin type O-GalNAc glycans. Table 1 summarizes all detected glycoprotein forms and gives a semi-quantitative overview. To prove the c/MAM glycosylation, O-glycans were released by reductive beta-elimination, purified via SPE cartridges and analyzed by PGC-LC-ESI-MS/MS.
Analysis of released glycans
The identified O-glycans were indeed mucin type core 1 and core 2 glycans (Fig. 2 and Supplementary Figure 3) with different modifications and degree of terminal sialylation. The well characterized bovine fetuin O-glycans (singly and doubly sialylated core 1 and doubly sialylated core 2 O-glycans) were used as reference samples [13] . The c/MAM glycans not only showed the same retention behavior on the hypercarb column but also gave the same fragmentation pattern in the CID-MS/ MS spectra as the fetuin O-glycans (data not shown). Two peaks were obtained for a singly sialylated core 2 glycan. Specific reporter ions in MS/MS spectra helped to resolve the main peak at 19.6 min as sialylated on the 6-arm (Supplementary Figure 3 , Panel C). The other glycan version with sialic acid on the 3-arm eluted some minutes earlier as had also been seen by Pabst et al. [14] . A very early eluting (8.1 min) monosialylated core 1 glycan (m/z 677.2, see Fig. 2 ) gave a fragment at 515 m/z (Neu5Ac-GalNAc-ol) in CID-MS/MS identifying the peak sialylated on the core- Protein forms with different degree of N-acetylhexosamines, hexoses and N-acetylneuraminic acid residues are marked with pXYZ. Protein forms lacking the N-terminal ETGA are marked with a # -most of these forms are however hidden under more intense peaks. Detected and calculated monoisotopic masses as well as the deviation between the two values are given. Differences in theses deviations among the distinct glycoprotein forms might originate from a suboptimal performance of the SNAP algorithm (calculating monoisotopic masses from deconvoluted data) on peaks with low signal to noise ratio and overlapping or disrupting peaks as the sample is very complex. A uniform deviation of the main peaks of 1 Da is probably caused by deamidation. Relative quantification is done in relation to the sum of all identified glycoprotein forms using peak intensity values GalNAc residue rather than on the galactose. The fully sialylated core-2 glycan was also found sulfated, however, MS/MS in both positive and negative ion mode could not reveal the exact position of sulfation in the glycan. Further minor glycan structures (with an additional HexNAc attached to the GlcNAc) were proven by CID-MS/MS (Supplementary Figure 3, Panel B) , whereas the position of a fucose on yet another core-2 glycan could not be resolved. Relative quantification of detected O-glycan species is given the supplementary table 1. It should be noted that examples of moderate glycan rearrangements -as expectable from previous observations [15] -were registered. While negative mode MS/MS is often regarded as favorable [16] , positive mode MS/MS combined with comparing the retention times on PGC with that of O-glycans from bovine fetuin resulted in unambiguous structural assignments of all except the very minor peaks.
Identification of the c/MAM glycopeptide
For further investigations of the complex glycosylation pattern and to prove that the modification sites are located in the region described in [10] , the c/MAM domain was digested with different proteases and the glycopeptides were characterized by RP-LC-ESI-CID-MS/MS. The use of the NetOGlyc 4.0 prediction tool for O-GalNac-glycosylation site mapping [10] suggested various amino acid candidates as being potentially modified. All of them were situated in the N-terminal part of the protein. Following protease treatment all peptides but the N-terminal peptide were identified as being non-glycosylated. The Oglycopeptide was, however, not found in a tryptic but in a chymotryptic digest, where glycan specific reporter ions (292, 366, etc.) in MS/MS spectra helped to identify the elution positions of the various glycoforms of the chymotryptic peptide ETGATEKPTVIDSTIQSEFPTY (Fig. 3 ). Other than with the fetuin O-glycopeptide, only one peak occurred per composition with the exception of the forms harboring 3N-acetylhexosamines, 3 hexoses and 6 sialic acid residues (gp336) and gp446. Nevertheless, preparative scale reversed phase fractionation of chymotryptic c/MAM-domain peptides was undertaken for site specific glycosylation analysis by ETD-MS/MS. Supplementary   Fig. 2 Analysis of released Oglycans. Reduced O-glycans as obtained by reductive β-elimination were separated by PGC-LC and detected by mass spectrometry [17, 18] .
Chymotryptic peptides were separated on a Bpreparativeĉ olumn using a proportionally scaled up gradient as used for capillary LC-ESI-MS. For correct pooling, all fractions were inspected by LC-ESI-MS on the Micromass Ultima Q-TOF instrument. Interestingly, the amaZon ion trap equipped with the standard ESI source was not capable of detecting all glycopeptide forms. Especially peptides with a high glycan content -in particular sialic acid -could not be found.
Determination of glycosylation sites and fine structure with ETD-MS/MS
A comparably poor performance of the ion trap was reported for synthetic sialylated N-glycopeptides [19] . In order to perform ETD-MS/MS on the amaZon ion trap, we aimed to find a solution for the said ionization problem with the standard ESI source that prevented ETD analysis of the more intensely glycosylated species in on-line LC and even in direct infusion mode. Nanospray LC-ESI with the nanoBooster CaptiveSpray source was recently reported to promote the ionization of (sialylated) glycopeptides [20] . In fact, the nanoBooster CaptiveSpray allowed ionization of all glycovariants sufficiently well to obtain useful ETD spectra, however, with the heavily glycosylated forms only when desialylated. Fortunately, in the particular case of Nrp1 Oglycosylation, desialylation did not lead to loss of information as all major structures were fully sialylated. With the Nrp1 glycopeptide being considerably smaller than the fetuin Oglycopeptide, ETD spectra could be obtained on an LC-ESI (rather than direct infusion) timescale using manual, targeted MS/MS mode, which permits dwell times of well over 1 min.
Precursor charge state emerged as a most relevant criterion for ETD of other compounds [21, 22] , it made little difference for Nrp1 glycopeptides. In contrast, co-eluting peptides severely affected ionization and hence fragmentation. Therefore, the prior fractionation step proved beneficial. Although nominally the same separation mechanism was applied, subtle differences in selectivity between preparative and analytical column led to more homogenous peaks on the latter. Forms with core 2 glycans only are displayed at the right side, whereas the variants with both types of core structures are shown in the middle. Forms marked in blue (e.g., gp448) were analyzed after desialylation. As all the major forms considered for determination of exact site occupancy were doubly sialylated (see Fig. 1 ), the full sialylation regalia of these glycopeptides could be re-constructed as shown. Glycan modifications on S13 and T14 could not be resolved in all glycopeptide species, ambiguities are marked with a line (e.g., gp558). Gp446 marked with a * could not be definitely confirmed or excluded
The smallest glycopeptide, gp112 (HexNAc 1 Hex 1 NeuAc 2 ), could readily be elucidated as bearing its doubly sialylated core-1 glycan on T5. Gp224 was modified at T5 and T14 but not S13 as derived from the albeit small c 13 ion (Fig. 4) .
With already six sialic acids, the poor ionization on the amaZon ion trap prevented gp336 ETD analysis and so it was the first glycopeptide subjected to desialylation by an α2-3,6,8 neuraminidase. Notably, only three sialic acids were removed this way -enough to provide a strong signal and ETD fragment spectra. At first, we regarded this partial desialylation as the incidental result of insufficient digestion conditions. However, the more highly sialylated structures exhibited an increasingly more complete removal of Neu5Ac with the core 2 type only species being fully desialylated. The overall pattern of incomplete desialylation compellingly implied that the GalNAc bound α2,6-Neu5Ac had resisted the neuraminidase treatment whereas the Gal-linked Neu5Ac residues had been quantitatively removed. A PGC-LC-MS/MS measurement of neuraminidase treated, β-eliminated O-glycans finally confirmed this hypothesis (Supplementary Figure 2) . Figure 5 gives an overview of the identified glycopeptide variants with glycans attached to specific amino acids. As mentioned before, glycopeptide forms with one or two glycans are always modified on T5 and T14, with T5 being favored over T14. Glycopeptide forms with three modification sites (gp336, gp446 and gp666) showed always occupation at T5 and T14 while usage of T9 or S13 was variable. The differential modification of T9 or S13 in gp336 and gp446 led to the separation of distinct glycoforms in reversed phase chromatography. The early eluting peaks were modified at S13, whereas the later eluting peaks were glycosylated at T9. In contrast, the attachment of os222 on different residues in gp446 did not alter its elution behavior and produced only one peak (Fig. 5) .
To conclude, the four sites T5, T9, S13 and T14 were found glycosylated. Interestingly, in gp666, gp778 and gp888, two rather bulky core-2 glycans were found on the neighboring amino acids S13 and T14. Three corresponding ETD spectra that were used for modification site determination are given in Fig. 4a-c . The gp224 and gp666 (measured as gp660) spectra were chosen as representing one natural and one desialylated glycopeptide. In each case, the yield of c-and z-fragment ions was sufficient for assigning the exact glycosylation sites. In many glycopeptide spectra, a loss of some parts of a glycan during the ETD reaction could be observed. Loss of single sialic acids in natural glycopeptide samples or of HexNAcHex (366.1 [M+H] + see Fig. 4 ) was observed. CID-like side reactions during ETD are known from literature [23, 24] and did not compromise the identification of glycan modification sites in any way. Figure 6c shows the ETD spectrum of gp334 that led to the identification of two different glycopeptide forms in the same sample.
When comparing the detected glycosylated amino acids with those proposed as modified by the O-GalNAc-site prediction tool NetOGlyc 4.0, an over-estimation of glycosylation sites could be seen. The software assessed all actually glycosylated sites as positive, however, also the sites T2, S17 and T21 were predicted to be modified when having a look at recombinant c/MAM domain. With the complete neuropilin-1 sequence, T21 (T645 on O14786 -NRP1_HUMAN) was interestingly not suggested to be glycosylated.
Substrate specificity of C. perfringens neuraminidase
The hypothesis that neuraminidase disdains the GalNAclinked Neu5Ac was tested with disialylated core 1 and core 2 O-glycans. In fact, the two Gal-linked sialic acids from core 2 glycans were readily removed and so was one Neu5Ac of the core 1 substrate (Supplementary Fig. 2 ). The remaining mono-sialylated structure was identified as Neu5Ac (Gal-)GalNAc by PGC-LC-MS/MS. In contrast to glycopeptide linked glycans, GalNAc-linked sialic acid was degraded from free glycans but so much slower that this neuraminidases specificity can be useful for discrimination of differently linked sialic acid.
Conclusion
Recombinantly expressed neuropilin-1 c/MAM-domain was found to be heavily O-glycosylated in the region recently reported as bearing several O-GalNAc residues when expressed in Simple Cells, which lack the ability to add the β1,3-Gal to the peptide bound GalNAc [10] . The main focus of this work was the comprehensive definition of the glycosylation sites and the attached glycans expressed by human cells with unquenched O-glycosylation capability. The O-glycans found were all fully sialylated in contrast to e.g., fetuin [11] with one glycan being sulfated as well.
ETD-MS/MS proved its reputation for being the method of choice for this kind of analysis [25, 26] , whereby the largest difficulty encountered with the highly sialylated neuropilin-1 glycopeptides was their poor ionization in the ESI source on the ion trap used for ETD.
A glycopeptide species pyramid with the major glycopeptide gives an overview of the analytical results (Fig. 6) . Four amino acids were identified to carry the O-glycan modifications (see Fig. 3b ).
The isomers found suggest some hierarchy in the order of O-glycan addition. T5 was found modified in all cases and thus constituted the first target of a polypeptide GalNAc-transferase, strictly followed by T14. The other two glycosylation sites (T9 and S13) were not subject to such strict hierarchy and can be seen as equal O-glycan acceptors. As both core-1 and core-2 O-glycans were found on each of the four amino acids, no preference of the processing glycosyltransferases for a certain site -as was seen in other studies [11] -could be observed. The rather equal amounts of core-1 and core-2 glycans observed on c/MAM implies a balance between the sialylation reaction of a T-antigen structure and the buildup of a core-2 structure (addition of a GlcNAc onto the T-antigen) [27] . While this study was conducted assuming that its results allow conclusions on natural neuropilin-1, it must be noted that the recombinant c/MAM domain dealt with in this study represents only a part of the human protein. Glycosylation site usage and glycosylation patterns thus may deviate to some extent between the natural form as and the domain expressed in human cells (HEK293).
The O-glycosylation region of neuropilin-1 is situated between two different outer membrane domains, the c/MAM domain and b2 domain [28] . Regarding the function of this O-glycosylation, it can only be speculated that the glycans may help this protein region to adopt the correct, stable conformation by forming a highly hydrophilic sleeve around the connecting peptide stretch. Another interesting fact is that a described glycosaminoglycan modification [3] , known to influence VEGF signaling, is only 16 aa upstream of the first detected O-GalNAc modification site. Thus, the heavy OGalNAc glycosylation in this part may also play some role in binding VEGFR2 or other binding partners as galectin-1. Certainly, future studies will have to illuminate the probable functions of this novel glycosylation.
Finally, two technical aspects shall be emphasized. First, very unlike N-glycopeptides of different glycan structure [12, 29] , O-glycopeptides of differing composition exhibit a large spread of elution times as seen with fetuin and again in this study. Second, the (recombinant) sialidase from Clostridium perfringens exhibited an as yet unnoticed substrate specificity in being almost inactive towards the GalNAc-linked α2,6-neuraminic acid in O-glycopeptides.
